Handelsbanken Fonder AB Purchases 3,400 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Handelsbanken Fonder AB lifted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 21.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 19,300 shares of the company’s stock after purchasing an additional 3,400 shares during the period. Handelsbanken Fonder AB’s holdings in Dyne Therapeutics were worth $693,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Concurrent Investment Advisors LLC bought a new position in shares of Dyne Therapeutics in the first quarter worth approximately $573,000. Sei Investments Co. purchased a new stake in Dyne Therapeutics in the first quarter worth $693,000. Oppenheimer & Co. Inc. purchased a new stake in Dyne Therapeutics in the first quarter worth $810,000. Seven Eight Capital LP purchased a new stake in Dyne Therapeutics in the first quarter worth $516,000. Finally, Swiss National Bank lifted its stake in Dyne Therapeutics by 41.5% in the first quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $2,419,000 after acquiring an additional 25,000 shares during the period. Institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DYN shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. JPMorgan Chase & Co. raised their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Finally, Morgan Stanley raised their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $33.67 on Friday. Dyne Therapeutics, Inc. has a one year low of $6.40 and a one year high of $47.45. The stock has a 50-day moving average of $38.37 and a 200 day moving average of $34.32. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of -8.48 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.02. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 135,304 shares of company stock worth $4,857,019. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.